Analyst Price Target is $89.00
▲ +38.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Belite Bio in the last 3 months. The average price target is $89.00, with a high forecast of $110.00 and a low forecast of $57.00. The average price target represents a 38.80% upside from the last price of $64.12.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Belite Bio. This Buy consensus rating has held steady for over two years.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Read More
